Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2056 to 2070 of 8933 results

  1. Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value Assessment: draft guidance

    We are listening to your views on this Health technology evaluation. Comments close 24 February 2026.

    Health technology evaluation
    In consultation

  2. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. SEEG-guided radiofrequency thermocoagulation in refractory epilepsy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Lumella Pre-Eclampsia Test (MT687)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  5. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 6 March 2026.

    Technology appraisal guidance
    In consultation

  6. Deutetrabenazine for treating tardive dyskinesia [ID6550]

    In development Reference number: GID-TA11718 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  8. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development Reference number: GID-TA11454 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  9. Filgotinib for treating axial spondyloarthritis [ID6594]

    In development Reference number: GID-TA11776 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]

    In development Reference number: GID-TA10223 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]

    In development Reference number: GID-TA11802 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]

    In development Reference number: GID-TA11780 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610]

    In development Reference number: GID-TA11850 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  14. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

    In development Reference number: GID-TA11468 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

    In development Reference number: GID-NG10469 Expected publication date: TBC

    NICE guideline
    In development